Idecabtagene Vicleucel Treatment Among Patients With R/R Multiple Myeloma

Results from a Multicenter Retrospective Study

According to findings of a multicenter retrospective study recently published in the Journal of Clinical Oncology, idecabtagene vicleucel treatment did not yield higher levels of efficacy or safety among patients with relapsed/refractory (R/R) multiple myeloma (MM) compared to results of a previous study. 

Idecabtagene vicleucel treatment was previously assessed in the phase 2 KarMMa trial, which demonstrated an overall survival rate of 73% and a complete response rate of 33%. In this trial, Dr Doris K Hansen, MD, Moffitt Cancer Center, Tampa, Florida, and coauthors aimed to reassess the efficacy and safety of idecabtagene vicleucel for patients with R/R MM, particularly those who were ineligible for the KarMMa trial. 

159 patients with R/R MM who had previously undergone leukapheresis were enrolled in this study at 11 US institutions to evaluate the standard of care of idecabtagene vicleucel. 75% (n=120) of all patients enrolled would have been ineligible for the KarMMA trial. All patients were assessed for toxicities and treatment-related adverse events, and were graded based on the International Myeloma Working Group criteria. 

Results indicated that grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 82/3% and 18/6%. The best overall survival rate was 84% and the best complete response rate was 42%. The median progression-free survival rate at a follow-up of 6.1 months was 8.5 months, with patients who had high-risk cytogenetics, B-cell maturation antigen–targeted therapy, and who were younger having inferior progression-free survival. 

As these results were similar to the results of the KarMMa trial, Dr Hansen et al concluded, “safety and efficacy of ide-cel in patients with RRMM in the [standard of care] setting were comparable with those in the phase II pivotal KarMMa trial despite most patients (75%) not meeting trial eligibility criteria.” 

Source: 

Hansen DK, Sidana S, Peres LC, et al. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol. Published online January 9, 2023. doi:https://doi.org/10.1200/jco.22.01365